CDK9-IN-19 is a potent and selective CDK9 inhibitor with an IC50 of 2.0 nM; it exhibits strong anti-proliferative activity against cancer cells, moderate pharmacokinetic properties, and low hERG inhibitory activity; it significantly suppresses tumor growth in the MV4-11 xenograft mouse model; it can be used for the study of acute myeloid leukemia (AML).